| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2020 | 209 | 2.280 |
Why?
|
| Cyclophosphamide | 14 | 2017 | 58 | 1.400 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2017 | 21 | 0.990 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 301 | 0.910 |
Why?
|
| Mammary Neoplasms, Experimental | 4 | 2017 | 69 | 0.850 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2023 | 290 | 0.800 |
Why?
|
| Cell Line, Tumor | 29 | 2023 | 2598 | 0.700 |
Why?
|
| Breast Neoplasms | 11 | 2022 | 1679 | 0.700 |
Why?
|
| Neoplasm Metastasis | 6 | 2013 | 233 | 0.670 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 23 | 0.670 |
Why?
|
| Angiogenesis Inhibitors | 9 | 2017 | 62 | 0.640 |
Why?
|
| Cell Proliferation | 11 | 2023 | 1420 | 0.630 |
Why?
|
| Mice | 36 | 2023 | 6490 | 0.610 |
Why?
|
| Neoplasms | 7 | 2017 | 1341 | 0.580 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 1554 | 0.530 |
Why?
|
| Neovascularization, Pathologic | 7 | 2017 | 137 | 0.520 |
Why?
|
| Cytokines | 1 | 2020 | 661 | 0.510 |
Why?
|
| Indoles | 5 | 2017 | 178 | 0.440 |
Why?
|
| Animals | 41 | 2024 | 16695 | 0.440 |
Why?
|
| Deoxycytidine | 2 | 2011 | 35 | 0.420 |
Why?
|
| DNA Repair | 2 | 2005 | 196 | 0.410 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2013 | 339 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2009 | 180 | 0.410 |
Why?
|
| Mice, SCID | 12 | 2018 | 158 | 0.410 |
Why?
|
| Melanoma | 3 | 2023 | 109 | 0.390 |
Why?
|
| Prodrugs | 1 | 2011 | 31 | 0.360 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2013 | 17 | 0.360 |
Why?
|
| Antibodies | 3 | 2009 | 140 | 0.350 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 479 | 0.350 |
Why?
|
| Pyrroles | 4 | 2017 | 68 | 0.350 |
Why?
|
| Humans | 50 | 2024 | 42163 | 0.350 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 979 | 0.340 |
Why?
|
| Neoplasm Transplantation | 7 | 2018 | 129 | 0.340 |
Why?
|
| Mice, Inbred BALB C | 8 | 2017 | 686 | 0.310 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 3 | 0.300 |
Why?
|
| Viscera | 1 | 2008 | 4 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 358 | 0.290 |
Why?
|
| Spheroids, Cellular | 3 | 2005 | 37 | 0.290 |
Why?
|
| Base Pair Mismatch | 2 | 2005 | 15 | 0.280 |
Why?
|
| Camptothecin | 2 | 2017 | 24 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2020 | 1112 | 0.270 |
Why?
|
| Endothelial Cells | 7 | 2017 | 324 | 0.270 |
Why?
|
| Female | 28 | 2022 | 24018 | 0.270 |
Why?
|
| Melanoma, Experimental | 3 | 2008 | 13 | 0.260 |
Why?
|
| Fibroblasts | 1 | 2009 | 278 | 0.260 |
Why?
|
| Thyroid Neoplasms | 2 | 2020 | 49 | 0.260 |
Why?
|
| Receptor, erbB-2 | 4 | 2022 | 149 | 0.250 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 3 | 0.250 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2006 | 2 | 0.250 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2006 | 2 | 0.250 |
Why?
|
| Bromocriptine | 1 | 2006 | 6 | 0.250 |
Why?
|
| Cushing Syndrome | 1 | 2006 | 5 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 310 | 0.250 |
Why?
|
| Tumor Cells, Cultured | 9 | 2011 | 506 | 0.240 |
Why?
|
| DNA Repair Enzymes | 1 | 2005 | 22 | 0.240 |
Why?
|
| Cyclin D1 | 3 | 2018 | 44 | 0.230 |
Why?
|
| Adenosine Triphosphatases | 1 | 2005 | 83 | 0.230 |
Why?
|
| Prostatic Neoplasms | 8 | 2013 | 1068 | 0.230 |
Why?
|
| Tumor Burden | 5 | 2012 | 84 | 0.230 |
Why?
|
| Vitamin B 12 | 1 | 2024 | 23 | 0.220 |
Why?
|
| Craniofacial Abnormalities | 1 | 2024 | 24 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2022 | 206 | 0.220 |
Why?
|
| Alkylating Agents | 1 | 2004 | 14 | 0.220 |
Why?
|
| Cell Movement | 3 | 2018 | 640 | 0.220 |
Why?
|
| Administration, Oral | 7 | 2016 | 256 | 0.210 |
Why?
|
| Colonic Neoplasms | 3 | 2017 | 223 | 0.210 |
Why?
|
| Survival Rate | 3 | 2020 | 353 | 0.210 |
Why?
|
| Mice, Nude | 10 | 2020 | 403 | 0.210 |
Why?
|
| Carrier Proteins | 1 | 2005 | 318 | 0.200 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 330 | 0.200 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 211 | 0.200 |
Why?
|
| Phenylurea Compounds | 2 | 2020 | 18 | 0.190 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 557 | 0.190 |
Why?
|
| Prognosis | 3 | 2020 | 850 | 0.180 |
Why?
|
| Apoptosis | 5 | 2017 | 1541 | 0.180 |
Why?
|
| Time Factors | 6 | 2017 | 1848 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1051 | 0.160 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 147 | 0.160 |
Why?
|
| Quinolines | 1 | 2020 | 76 | 0.160 |
Why?
|
| Blotting, Western | 4 | 2005 | 884 | 0.160 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1999 | 47 | 0.150 |
Why?
|
| Transplantation, Heterologous | 4 | 2018 | 98 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 32 | 0.150 |
Why?
|
| Thrombospondin 1 | 2 | 2012 | 23 | 0.150 |
Why?
|
| Molecular Probe Techniques | 1 | 2018 | 7 | 0.150 |
Why?
|
| Axilla | 1 | 2018 | 6 | 0.140 |
Why?
|
| Flavones | 1 | 2018 | 10 | 0.140 |
Why?
|
| Molecular Probes | 1 | 2018 | 23 | 0.140 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 38 | 0.140 |
Why?
|
| Taxoids | 2 | 2014 | 50 | 0.130 |
Why?
|
| Cell Death | 1 | 2017 | 277 | 0.130 |
Why?
|
| Base Sequence | 5 | 2004 | 997 | 0.130 |
Why?
|
| Annexin A6 | 1 | 1996 | 17 | 0.130 |
Why?
|
| Blotting, Northern | 3 | 2004 | 149 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 130 | 0.120 |
Why?
|
| Cisplatin | 3 | 2005 | 91 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 48 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2015 | 683 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2016 | 106 | 0.120 |
Why?
|
| Male | 20 | 2023 | 22779 | 0.120 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 223 | 0.120 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2016 | 94 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 379 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2017 | 2111 | 0.120 |
Why?
|
| Molecular Sequence Data | 5 | 2004 | 1559 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 159 | 0.120 |
Why?
|
| Up-Regulation | 5 | 2015 | 534 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2018 | 933 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2017 | 355 | 0.110 |
Why?
|
| Cell Adhesion | 1 | 2015 | 237 | 0.110 |
Why?
|
| Curcumin | 1 | 2016 | 115 | 0.110 |
Why?
|
| Disease Progression | 3 | 2014 | 661 | 0.110 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 153 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 297 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 158 | 0.110 |
Why?
|
| Mutation | 3 | 2024 | 1169 | 0.100 |
Why?
|
| Ultrasonic Therapy | 1 | 2013 | 4 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 122 | 0.100 |
Why?
|
| Receptor, Endothelin B | 1 | 2012 | 4 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2012 | 10 | 0.100 |
Why?
|
| Caveolin 1 | 1 | 2012 | 33 | 0.100 |
Why?
|
| Ceramides | 1 | 2012 | 43 | 0.090 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 287 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 26 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2011 | 36 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 189 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 152 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 129 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 9 | 0.090 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2010 | 21 | 0.080 |
Why?
|
| Genetic Engineering | 1 | 2010 | 36 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 649 | 0.080 |
Why?
|
| Drug Synergism | 3 | 2017 | 189 | 0.080 |
Why?
|
| Pyridines | 1 | 2010 | 134 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 206 | 0.080 |
Why?
|
| Transfection | 2 | 2015 | 526 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2022 | 1265 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 454 | 0.080 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2009 | 18 | 0.080 |
Why?
|
| Lymphokines | 1 | 2009 | 17 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 30 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 158 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 658 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2009 | 137 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2020 | 134 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 273 | 0.070 |
Why?
|
| Cell Cycle | 3 | 2017 | 348 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2022 | 452 | 0.060 |
Why?
|
| Azacitidine | 1 | 2005 | 22 | 0.060 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2005 | 8 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 34 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2005 | 29 | 0.060 |
Why?
|
| Neural Crest | 1 | 2024 | 27 | 0.060 |
Why?
|
| CHO Cells | 1 | 2004 | 123 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2014 | 1586 | 0.050 |
Why?
|
| Gene Expression | 2 | 2018 | 692 | 0.050 |
Why?
|
| Cricetinae | 1 | 2004 | 241 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2004 | 181 | 0.050 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2023 | 9 | 0.050 |
Why?
|
| HT29 Cells | 3 | 2012 | 60 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 366 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 24 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 134 | 0.050 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2003 | 31 | 0.050 |
Why?
|
| Zebrafish | 1 | 2024 | 146 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 427 | 0.050 |
Why?
|
| Cadherins | 1 | 2004 | 102 | 0.050 |
Why?
|
| Topotecan | 2 | 2013 | 5 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 534 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 18 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 508 | 0.050 |
Why?
|
| Anoikis | 1 | 2022 | 21 | 0.050 |
Why?
|
| RNA | 1 | 2004 | 266 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 928 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2013 | 362 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2005 | 393 | 0.050 |
Why?
|
| Phenotype | 1 | 2024 | 774 | 0.050 |
Why?
|
| Vinblastine | 2 | 2016 | 9 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 261 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 1999 | 318 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 228 | 0.040 |
Why?
|
| Middle Aged | 3 | 2016 | 11819 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2016 | 411 | 0.040 |
Why?
|
| Protein Phosphatase 2 | 1 | 1999 | 25 | 0.040 |
Why?
|
| Aged | 3 | 2017 | 7982 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 15 | 0.040 |
Why?
|
| Tegafur | 2 | 2010 | 3 | 0.040 |
Why?
|
| Uracil | 2 | 2010 | 9 | 0.040 |
Why?
|
| Rabbits | 2 | 1996 | 292 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 502 | 0.040 |
Why?
|
| Fluorouracil | 2 | 2012 | 46 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 26 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2011 | 11 | 0.040 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2017 | 3 | 0.040 |
Why?
|
| bcl-X Protein | 1 | 2017 | 27 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 93 | 0.030 |
Why?
|
| Contrast Media | 1 | 2018 | 101 | 0.030 |
Why?
|
| Caspases | 1 | 2017 | 148 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 221 | 0.030 |
Why?
|
| Nevus | 1 | 1996 | 5 | 0.030 |
Why?
|
| Stem Cells | 2 | 2010 | 151 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 81 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2016 | 55 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 230 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 94 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2015 | 18 | 0.030 |
Why?
|
| RNA Stability | 1 | 2015 | 28 | 0.030 |
Why?
|
| Cell Line | 1 | 1999 | 1416 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 62 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 112 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-2B | 1 | 1994 | 1 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 1994 | 18 | 0.030 |
Why?
|
| Fecal Impaction | 1 | 2013 | 1 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1994 | 110 | 0.030 |
Why?
|
| Rats, Nude | 1 | 2013 | 6 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Species Specificity | 1 | 2013 | 279 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2012 | 10 | 0.020 |
Why?
|
| Leucovorin | 1 | 2012 | 5 | 0.020 |
Why?
|
| Cell Division | 2 | 2004 | 314 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 18 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 2012 | 30 | 0.020 |
Why?
|
| Injections | 1 | 2012 | 40 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 284 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 185 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 103 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 53 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 1574 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 100 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 1076 | 0.020 |
Why?
|
| Proteins | 1 | 1994 | 383 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 16 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2008 | 1804 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 973 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2005 | 1617 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 2803 | 0.020 |
Why?
|
| Liver | 2 | 2007 | 503 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 21 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2008 | 62 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 249 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 134 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2007 | 16 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 387 | 0.020 |
Why?
|
| Biotransformation | 1 | 2007 | 68 | 0.020 |
Why?
|
| Laminin | 1 | 2007 | 58 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2007 | 49 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 102 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2007 | 71 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 99 | 0.020 |
Why?
|
| Collagen | 1 | 2007 | 178 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 43 | 0.020 |
Why?
|
| Triazines | 1 | 2006 | 25 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 599 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 57 | 0.020 |
Why?
|
| Thromboplastin | 1 | 2005 | 6 | 0.010 |
Why?
|
| Propionates | 1 | 2005 | 27 | 0.010 |
Why?
|
| Quinazolines | 1 | 2005 | 37 | 0.010 |
Why?
|
| Rats | 1 | 2013 | 3701 | 0.010 |
Why?
|
| Piperidines | 1 | 2005 | 80 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 217 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2004 | 12 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2004 | 35 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2004 | 17 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 602 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 174 | 0.010 |
Why?
|
| Etoposide | 1 | 2004 | 21 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2004 | 80 | 0.010 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2003 | 3 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2003 | 18 | 0.010 |
Why?
|
| Microdissection | 1 | 2003 | 13 | 0.010 |
Why?
|
| Microcirculation | 1 | 2003 | 40 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2004 | 80 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 25 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2003 | 52 | 0.010 |
Why?
|
| Wound Healing | 1 | 2004 | 82 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 97 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 64 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 131 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2004 | 124 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 12 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 12 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 428 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 30 | 0.010 |
Why?
|
| Drinking | 1 | 2002 | 35 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1066 | 0.010 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 1994 | 33 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1994 | 54 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1994 | 195 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 1994 | 143 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 1994 | 267 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 1188 | 0.010 |
Why?
|